Last €0.36 EUR
Change Today 0.00 / 0.00%
Volume 0.0
As of 2:08 AM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

e-therapeutics plc (3AQ) Snapshot

Open
€0.36
Previous Close
€0.36
Day High
€0.36
Day Low
€0.36
52 Week High
05/14/14 - €0.41
52 Week Low
03/19/14 - €0.22
Market Cap
94.3M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
264.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for E-THERAPEUTICS PLC (3AQ)

Related News

No related news articles were found.

e-therapeutics plc (3AQ) Related Businessweek News

No Related Businessweek News Found

e-therapeutics plc (3AQ) Details

e-Therapeutics plc is engaged in the discovery and development of drugs through its proprietary platform in network pharmacology. The company focuses on the discovery of drugs for cancer and degenerative diseases of the nervous system. Its drug candidates include ETS2101, which is in Phase I clinical trial for the treatment of brain cancer in the United States, and for the treatment of solid tumors in the United Kingdom; ETS6103, a Phase IIb trial product for depressive disorders; and ETX1153c, an anti-infective drug candidate that is in preclinical stage for the treatment of C. difficile infection. The company was founded in 2001 and is based in Long Hanborough, the United Kingdom.

21 Employees
Last Reported Date: 05/30/14
Founded in 2001

e-therapeutics plc (3AQ) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: 444.0K GBP
Development Director and Executive Director
Total Annual Compensation: 262.0K GBP
Compensation as of Fiscal Year 2014.

e-therapeutics plc (3AQ) Key Developments

e-Therapeutics plc., Annual General Meeting, Jul 09, 2014

e-Therapeutics plc., Annual General Meeting, Jul 09, 2014., at 11:00 GMT Standard Time. Location: at the offices of Bond Dickinson LLP.

e-Therapeutics Plc. Reports Consolidated Earnings and Company Cash Flow Results for the Year Ended January 31, 2014

e-Therapeutics plc reported consolidated earnings and company cash flow results for the year ended January 31, 2014. For the year, the company has reported that loss for the year was GBP 5.039 million, or a loss of 1.98 pence per share, compared to a loss of GBP 4.178 million, or a loss of 3.02 pence per share, for the same period a year ago. Operating loss was GBP 6.719 million, compared to an operating loss of GBP 5.247 million for the same period a year ago. Loss before taxation was GBP 6.102 million, compared to a loss before taxation of GBP 5.024 million for the same period a year ago. Net cash used in operating activities was GBP 5.720 million compared to GBP 4.163 million a year ago. Acquisition of property, plant and equipment was GBP 22,000 compared to GBP 60,000 a year ago. Acquisition of other intangible assets was GBP 150,000 compared to GBP 189,000 a year ago. For the company, net cash used in operating activities was GBP 5.720 million compared to GBP 4.163 million a year ago. Acquisition of property, plant and equipment was GBP 22,000 compared to GBP 60,000 a year ago. Acquisition of other intangible assets was GBP 150,000 compared to GBP 189,000 a year ago.

e-Therapeutics Announces Recruitment Resumes into US Phase I ETS2101 Brain Cancer Trial

e-Therapeutics plc announced that the US Food and Drug Administration (FDA) has approved the resumption of recruitment of new patients into the company's investigator-led Phase Ia study of ETS2101 in brain cancer, conducted at the University of California San Diego Moores Cancer Centre. Recruitment was temporarily paused due to a drug storage issue which has been resolved to the satisfaction of the FDA, allowing the trial to continue to higher doses in further cohorts of patients. Patients who had received treatment with ETS2101 at the time of the temporary halt in recruitment were able to continue to be dosed in accordance with trial protocols.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
3AQ:GR €0.36 EUR 0.00

3AQ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 3AQ.
View Industry Companies
 

Industry Analysis

3AQ

Industry Average

Valuation 3AQ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact E-THERAPEUTICS PLC, please visit www.etherapeutics.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.